• Info on our Ph 2 Study of STK-012 in Lung Cancer
  • Careers
  • Contact
Synthekine
  • About Us
    • Our Story
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Our Partners
  • Our Platforms
    • About Cytokines
    • Cytokine Engineering Platforms
    • Posters and Publications
  • Our Pipeline
    • Pipeline
    • STK-012
    • Expanded Access Policy
    • Legacy Programs
  • News
    • Press Releases
  • Twitter
  • Linked In
  • Menu Menu
  • About Us
    • Our Story
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Our Partners
  • Our Platforms
    • About Cytokines
    • Protein Engineering Platforms
    • Posters and Publications
  • Our Pipeline
    • Pipeline
    • STK-012
    • STK-009 + SYNCAR-001
    • Additional Programs
  • News
    • Press Releases
  • Careers
  • Contact
  • Info on our Ph 2 Study of STK-012 in Lung Cancer
  • Twitter
  • Linked In

header_svg_v3

November 17, 2021/by David Anderson

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/logo-300x63.png 0 0 David Anderson /wp-content/uploads/logo-300x63.png David Anderson2021-11-17 23:44:002021-11-17 23:44:00header_svg_v3
  • About Us
    • Our Story
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Our Partners
  • Our Platforms
    • About Cytokines
    • Cytokine Engineering Platforms
    • Posters and Publications
  • Our Pipeline
    • Pipeline
    • STK-012
    • Expanded Access Policy
    • Legacy Programs
  • News
    • Press Releases
  • Twitter
  • Linked In
  • Info on our Ph 2 Study of STK-012 in Lung Cancer
  • Careers
  • Contact

Copyright 2025 – Synthekine

Scroll to top Scroll to top Scroll to top